Associated tags: KTTA, Research, Pharmaceutical industry, Patient, Therapy, MIAMI, Central nervous system, Psychiatry, Psychopharmacology, Biotechnology, CNS, Ketamine
Retrieved on:
Thursday, November 9, 2023
Survival,
PNAS,
IND,
Stanford University,
Patent,
SOD1,
KTTA,
Clinical professor,
Behavior,
National academy,
CNS,
Natalizumab,
Research,
HIV disease progression rates,
FN,
Oregon Health & Science University,
Disease,
ALS,
Multiple sclerosis,
Integrin,
Patient,
Mayo Clinic,
MS,
SAN,
Central nervous system,
Pharmaceutical industry,
Pasithea (Charites),
Nature SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).
Key Points:
- Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
- This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
- Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
- Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.
Retrieved on:
Thursday, September 14, 2023
Central nervous system,
PALO,
Research,
MEK,
CNS,
Suite,
Share repurchase,
KTTA,
Hand,
ALS,
Alpha-5 beta-1,
Pharmaceutical industry,
Cryptocurrency,
Security (finance),
Telephone,
Pasithea (Charites) The tender offer expired at 5:00 p.m. on September 8, 2023 and was funded entirely through the Company’s cash on hand.
Key Points:
- The tender offer expired at 5:00 p.m. on September 8, 2023 and was funded entirely through the Company’s cash on hand.
- Based on the final results, a total of 5,323,451 shares of common stock were validly tendered and not withdrawn.
- Broadridge Corporate Issuer Solutions, LLC (“Broadridge”), the depositary for the tender offer, will promptly pay for all of the shares of common stock accepted for purchase in accordance with the terms and conditions of the tender offer.
- For all questions relating to the tender offer, please contact: Secretary, Pasithea Therapeutics Corp., 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139, Email [email protected], Telephone (786) 977-3380 or Broadridge Corporate Issuer Solutions, LLC, Telephone (855) 793-5068, email [email protected].
Retrieved on:
Thursday, September 7, 2023
PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
Key Points:
- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
- Attendees interested in 1 x 1 meetings are invited to request them through the conference’s meeting scheduler at [email protected] or by calling or emailing the company contact below.
Tissue,
Myelocyte,
National academy,
PNAS,
Central nervous system,
Mayo Clinic,
Macrophage,
Stanford University,
Oregon Health & Science University,
PALO,
Survival,
Research,
SOD1,
CNS,
Brain cell,
KTTA,
Gold,
HIV disease progression rates,
Patient,
Ras Al Khaimah Medical and Health Sciences University,
Integrin,
Microglia,
Clinical professor,
ALS,
Peripheral nervous system,
Pharmaceutical industry,
Vaccine,
Pasithea (Charites) PALO ALTO, Calif. and MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS), related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 (α5) integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients.
Key Points:
- “This work began at Stanford University, where we have spent decades studying integrin related targets,” commented Pasithea's Chairman, Dr. Larry Steinman.
- “It was especially gratifying to see the α5 antibody survival and behavioral benefits replicated at an independent CRO.
- These results provide novel data on the role and spatial distribution of α5 integrin in ALS and provide efficacy data of anti-α5 integrin treatment in the SOD1G93A mouse model, the gold standard preclinical ALS model.
- We believe this treatment may be used as a monotherapy or in combination with existing standard of care in both sporadic and genetic type of ALS.
Central nervous system,
Tender offer,
PALO,
Research,
CNS,
Bangladesh Securities and Exchange Commission,
Tender board,
Suite,
KTTA,
Tender,
Security (finance),
Letter,
Cryptocurrency,
Telephone Pasithea’s executive officers and directors have informed the Company that they do not intend to tender any shares of common stock in the Tender Offer.
Key Points:
- Pasithea’s executive officers and directors have informed the Company that they do not intend to tender any shares of common stock in the Tender Offer.
- To the extent the Tender Offer is oversubscribed, the Company will accept shares for purchase in the Tender Offer on a pro rata basis.
- Pasithea has not commenced the Tender Offer, and the description of the Tender Offer contained in this press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Pasithea.
- There can be no assurance that any tender offer will be commenced or if commenced that it will be consummated.
PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today confirmed that an independent special committee (“Special Committee”) of its Board of Directors (“Board”) thoroughly reviewed and rejected an unsolicited, non-binding proposal from Lucy Scientific Discovery, Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
Key Points:
- PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today confirmed that an independent special committee (“Special Committee”) of its Board of Directors (“Board”) thoroughly reviewed and rejected an unsolicited, non-binding proposal from Lucy Scientific Discovery, Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
- After a comprehensive review, conducted in consultation with its independent financial and legal advisors, the Special Committee determined that the Lucy proposal does not reflect Pasithea’s strategic value and prospects for continued growth and, as such, is not in the best interests of the Company or its stockholders.
PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirms its Board of Directors (“Board”) has previously formed a special committee of independent and disinterested directors (the "Special Committee") to assess an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
Key Points:
- PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirms its Board of Directors (“Board”) has previously formed a special committee of independent and disinterested directors (the "Special Committee") to assess an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
- Consistent with its fiduciary obligations to all shareholders, the Special Committee continues to actively evaluate the Lucy proposal, in consultation with its independent financial advisor, H.C. Wainwright & Co., and its legal advisors, Lowenstein Sandler LLP and Richards Layton & Finger, P.A.
- The Special Committee is comprised of independent directors Simon Dumesnil and Alfred Novak.
- Pasithea shareholders do not need to take any action at this time.
GMP,
PK,
Wuxi,
Partnership,
Central nervous system,
PALO,
CMC,
API,
MEK inhibitor,
Research,
Chemistry,
KTTA,
Investigational New Drug,
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
IND,
Food,
Safety,
Pharmaceutical industry,
Fine chemical,
Pasithea (Charites) GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food and Drug Administration (“FDA”) in the second half of 2023.
Key Points:
- GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food and Drug Administration (“FDA”) in the second half of 2023.
- The Company intends to utilize this supply of PAS-004 for its upcoming Phase I clinical trial.
- Dr. Tiago Reis Marques, Pasithea’s Chief Executive Officer, commented “We are pleased to have reached this milestone efficiently and on time.
- We are grateful to WuXi STA for its expertise throughout the process, development and manufacturing of the API.
PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
Key Points:
- PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
- Pasithea’s Board of Directors and management team regularly review opportunities to generate shareholder value and are committed to acting in the best interests of all shareholders.
- Consistent with its fiduciary duties, Pasithea’s Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the proposal from Lucy to determine the course of action that it believes is in the best interests of the Company and its shareholders.
- Pasithea shareholders do not need to take any action at this time.
Medical school,
Indiana University,
NF,
Central nervous system,
PALO,
Research,
MEK,
CNS,
Model,
Neurofibroma,
KTTA,
School,
Conference,
Neurofibromatosis,
Pharmaceutical industry PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis (NF) Conference taking place June 24-27, 2023, in Scottsdale, Arizona.
Key Points:
- PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis (NF) Conference taking place June 24-27, 2023, in Scottsdale, Arizona.
- “We are extremely pleased to be presenting preclinical data from PAS-004 conducted in collaboration with Dr. Wade Clapp at Indiana University, School of Medicine,” commented Dr. Graeme Currie, Pasithea’s Chief Development Officer.
- “The presentation will provide insight into PAS-004 efficacy and support further development of our lead candidate.”
Findings will be shared on a poster entitled “Evaluation of the Effects of a Novel MEK inhibitor PAS-004 in Plexiform Neurofibroma in a Pre-clinical Mouse Model of Neurofibromatosis Type 1”.
- Poster will be available to view during the 2023 NF Conference on the evening of Sunday, June 25th, from 5:00pm - 7:00pm.
